Dr. Jack Cush reviews the notable standouts in the news since the 1st of January. Surprising reports on ferritin, alcohol benefits, cannabis for pain and a lower dementia risk with hydroxychloroquine. Here are the links below.
A population-based retrospective cohort study patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE.
Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and an international research team discovered.
Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term corticosteroids.
The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. The full document and guideline can be found in the Annals of Internal Medicine.
In states with legalized medical cannabis use, 3 in 10 persons are using cannabis to manage their pain.
Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists:
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
